Tamoxifen chemical structure
Find information on thousands of medical conditions and prescription drugs.

Tamoxifen

Tamoxifen is an oral selective estrogen receptor modulator which is used in breast cancer treatment, and is currently the world's largest selling breast cancer treatment. It is used for the treatment of early and advanced breast cancer in pre- and post-menopausal women. It is also approved by the FDA for the reduction of the incidence of breast cancer in women at high risk of developing the disease. It has been further approved for the reduction of contralateral (in the opposite breast) breast cancer. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Tamoxifen was invented by ICI Pharmaceuticals (now AstraZeneca) and is sold under the brand names Nolvadex, Istubal, and Valodex. It is also available as a generic drug in a number of countries. In the United States, the drug was almost always referred by its generic name, even before patent expiration.

4-hydroxytamoxifen

4-hydroxytamoxifen is a form of the drug tamoxifen that is made by the body after taking tamoxifen. It can also be made in the laboratory, and may help decrease breast density. A topical form of 4-hydroxytamoxifen is being studied in breast cancer screening.

Links

  • STAR: a head-to-head comparison of tamoxifen and raloxifene as breast-cancer preventatives

Read more at Wikipedia.org


[List your site here Free!]


Benefits of tamoxifen for breast cancer prevention do not always outweigh overall risks - Patient-Oriented Evidence that Matters - Abstract
From Journal of Family Practice, 12/1/02 by Carmen Strickland

IBIS Investigators First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet 2002; 360:817 24.

* BACKGROUND Results have been mixed from 3 previous clinical trials of the use of tamoxifen for preventing breast cancer in high-risk women. A recently updated analysis from 1 negative study showed a decrease in the incidence of estrogen-receptor-positive breast cancer, adding support for the effectiveness of tamoxifen in some high-risk women. Tamoxifen therapy, however, is associated with significant adverse outcomes that may outweigh any benefits.

* POPULATION STUDIED Recruitment took place among outpatients at breast screening centers, primary care offices, and family history clinics. The media and contact of relatives of women with breast cancer provided additional recruitment. Women aged 35 to 70 years met criteria for entry if their risk for developing breast cancer was at least double that for women between 45 and 70 years, at least 4 fold that for women between 40 and 44 years, and 10-fold that for women aged 35 to 39 years. Risk was determined by an unpublished alternative to the Gail model. Patients were excluded if they had current or desired pregnancy, previous invasive cancer, previous deep vein thrombosis or pulmonary embolism, current use of anticoagulant agents, or a life expectancy of less than 10 years.

* STUDY DESIGN AND VALIDITY In this randomized, placebo-controlled, double-blinded trial, eligible women were randomized to receive either 20 mg tamoxifen (N=3573) or a matched placebo (N=3566) daily for 5 years. Thirteen women with findings on mammogram at the time of randomization were excluded from subsequent analysis. Participants received clinical evaluations every 6 months during the 5-year active treatment interval. Follow-up continued for up to 5 years beyond treatment by annual questionnaire or clinical visit. Symptoms, side effects, diagnoses, procedures, and concomitant medications were recorded at each evaluation. A mammogram was performed every 12 to 18 months. External reviewers, masked to treatment allocation, evaluated all end points and deaths.

Several features of the study design ensured internal validity. Randomization occurred by contact with a central office and was stratified by study center. Initial blocks of 8 were randomly distributed into blocks of 6 to 10 to ensure full masking. Analysis was performed on an intention-to-treat basis. Median follow-up was 50 months and the authors estimated that full compliance to 5 years was 64% in the tamoxifen group and 74% in the placebo group, although actual numbers of patients lost to follow-up were not provided. At the end of the data collection period, only 25% of women had completed a full 5 years of treatment (26.9% placebo vs 23.4% tamoxifen).

* OUTCOMES MEASURED The primary outcome measure was the frequency of breast cancer including ductal carcinoma in situ. Secondary outcomes included side effects, thromboembolic events, procedures, and deaths.

* RESULTS Women given tamoxifen had fewer breast cancers (n=60, 1.9%) than individuals given placebo (n=101, 2.8%; numbers needed to treat=112 for 5 years of treatment). As expected, prevention occurred at a cost of a greater incidence of venous thromboembolic events (1.2% vs 0.5%; numbers needed to harm [NNH]=137 for 5 years of treatment) and symptoms such as hot flashes and breast tenderness, and procedures including dilation and curettage and hysterectomy. More importantly, significantly more women on tamoxifen (n=25, 0.7%) died as compared with those on placebo (n=11, 0.3%; NNH=256 for 5 years of treatment).

RECOMMENDATIONS FOR CLINICAL PRACTICE

In women at high risk of breast cancer, tamoxifen is effective in reducing the incidence of the disease. The intervention, however, is associated with significant risk. During the 5-year period of this study, although the number of breast cancers was reduced, the number of serious adverse effects and deaths were higher in the treated group. Women at a lower risk of breast cancer than those studied would be even less likely to benefit from tamoxifen while risking the same serious adverse outcomes. For the small proportion of women with a high risk of breast cancer and a low risk of adverse events, discussion of this intervention may be warranted.

COPYRIGHT 2002 Dowden Health Media, Inc.
COPYRIGHT 2002 Gale Group

Return to Tamoxifen
Home Contact Resources Exchange Links ebay